Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 85Lymphoma, Follicular 53Lymphoma 50Lymphoma, Non-Hodgkin 47Lymphoma, Mantle-Cell 45Lymphoma, B-Cell, Marginal Zone 45Leukemia, Lymphocytic, Chronic, B-Cell 40Lymphoma, B-Cell 31Recurrence 20Burkitt Lymphoma 20Waldenstrom Macroglobulinemia 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasms 16Leukemia 11Leukemia, Hairy Cell 7Lymphoproliferative Disorders 5Hodgkin Disease 5Hematologic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Dendritic Cell Sarcoma, Interdigitating 4Neoplasm, Residual 3Lymphoma, AIDS-Related 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Epstein-Barr Virus Infections 3beta-Thalassemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Whole-Body Irradiation 7fludarabine 6Mycophenolic Acid 6Cyclophosphamide 6fludarabine phosphate 5Sirolimus 4Cyclosporine 4Peripheral Blood Stem Cell Transplantation 3Cyclosporins 3ibrutinib 2acalabrutinib 2Rituximab 2Melphalan 2venetoclax 1treosulfan 1tafasitamab 1obinutuzumab 1Valganciclovir 1Therapeutics 1Tacrolimus 1Stem Cell Transplantation 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1Mesna 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Ganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic × Rituximab × 1 year × Clear all
NCT02007044 2026-05-20

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
66 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Acerta Pharma BV

Phase 1 Completed
69 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡